...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Gilead GS-5829 Perspective
4
Jul 20, 2017 12:26PM
3
Jul 21, 2017 02:54PM
3
Jul 22, 2017 04:44PM

Toinv - Your excitement about Zenith is exactly why they are still a private company. They are in the middle of a Phase I trial, it takes time, waiting is not what many investors like to do. We will hear an update sometime in the next few months but until then it's twittle your thumbs time. Don't take lack of promotion as a sign of lack of activity at the corporate level. I think there is a reasonable opportunity that we could be pleasantly surprised this fall. Having one or more patients in a Phase I trial still alive after about a year now when they weren't expected to live 3 months is about as exciting as seeing visible gold in drill core of a gold exploration company. Our challeng as shareholders is to put this into perspective. We take a year to get to this point as a biotech and the mining company takes about 6 weeks. 

Hang in there baby, the fat lady aint singing yet.

tada

1
Jul 24, 2017 10:51AM
Share
New Message
Please login to post a reply